AbbVie petitions trade commission to ban Alvotech's Humira biosimilar; Cytokinetics licenses heart drug to Chinese partner
The AbbVie/Alvotech debacle on a Humira biosimilar has taken yet another turn — escalating tensions between the two biotechs.
As first reported by STAT News, the pharma giant filed a complaint with the US International Trade Commission on Friday, trying to prevent Alvotech from selling a lower cost version of AbbVie’s Humira, an anti-TNF drug that treats rheumatoid arthritis, ankylosing spondylitis and Crohn’s disease, among other ailments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.